

Ophthalmology Times Research Scholar Honoree Program

Systemic Medication Use with the Incidence and Growth of Geographic Atrophy

Delu Song, MD, PhD, MTR Scheie Eye Institute, University of Pennsylvania Nov 5, 2020



Financial disclosures:



This project was supported by NIH U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, U10 EY023530 and R21EY028998.



My role in this research:




Conception and design of the work/project
Analysis and interpretation of data
Creation and/or critical review of the presentation



Background




The projected number of people with age-related macular degeneration (AMD) in 2020 is 196 million, increasing to 288 million in 2040*.



Geographic atrophy (GA) is characterized by loss of retinal photoreceptors, RPE, and choriocapillaris.





Ophthalmology Times Research Scholar Honoree Program



"Will taking a beta-blocker interfere with my AMD?"



Ophthalmology Volume 124, Issue 3, March 2017, Pages 409-411



Report

 β -blockers and Neovascular Age-related Macular Degeneration

Ling Yeung MD ^{1, 2}, Ting-Shuo Huang MD, PhD ^{3, 4, 5, 6}, Yun-Hsuan Lin MD ¹, Kuang-Hung Hsu PhD ^{7, 8}, Jerry Chien-Chieh Huang MD ^{1, 2}, Chi-Chin Sun MD, PhD ^{1, 4, 5} A

Published in final edited form as: *Retina.* 2019 May ; 39(5): 918–925. doi:10.1097/IAE.00000000002059.

Systemic Beta-Blockers and Risk of Progression to Neovascular Age-related Macular Degeneration

Anton M. Kolomeyer, MD, PhD¹, Maureen G. Maguire, PhD^{2,3}, Wei Pan, MS², and Brian L. VanderBeek, MD, MPH, MSCE^{1,3,4}



Original Contribution

December 19, 2012

Long-term Use of Aspirin and Age-Related Macular Degeneration

Barbara E. K. Klein, MD, MPH; Kerri P. Howard, MS; Ronald E. Gangnon, PhD; Jennifer O. Dreyer, BS; Kristine E. Lee, MS; Ronald Klein, MD, MPH



The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies

Age-Related Eye Disease Study 2 Report No. 20





Purpose:



To determine associations of <u>systemic medications</u> with the <u>incidence</u> <u>and growth of GA</u> in participants of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)



Exposure:

Systemic medications

- Cholinesterase inhibitor
- ACE inhibitors
- Calcium channel blockers
- Beta-blockers
- Diuretics
- Aspirin

- Steroids
- Statins
- Hormone replacement therapy
- Antacids
- Drugs targeting G protein-coupled receptors.






Methods:



• CATT is a multicenter, prospective, noninferiority, clinic trial evaluating the safety and efficacy of ranibizumab or bevacizumab in the treatment of exudative AMD.



Methods:



- The GA was defined as a partial or complete depigmentation of one or more patches $\geq 250 \ \mu$ in longest linear dimension in the macula in the color fundus photos.
- The area of individual GA lesion was measured manually with Image J.



Methods:




- Univariable and multivariable Cox regression models were used in assessing the association between <u>systemic medication and GA</u> <u>incidence</u>.
- Univariable and multivariable mixed effects models were used in assessing the association between <u>systemic medication and GA growth</u>.




Results:



Flow chart for the study eye <u>GA incidence</u> analysis cohort







The baseline characteristics of study eye GA incidence cohort and GA growth cohort

Baseline Characteristics	GA Incidence Cohort	GA Growth Cohort
	(N=1011)	(N=214)
Baseline age: Mean (SD)	78.9 (7.6)	80.6 (6.4)
Gender: Female (%)	623 (61.6%)	136 (63.6%)
Smoking Status		
Never	436 (43.1%)	94 (43.9%)
Former	491 (48.6%)	106 (49.5%)
Current	84 (8.3%)	14 (6.5%)
Randomized Treatment Drug		
Ranibizumab	517 (51.1%)	118 (55.1%)
Bevacizumab	494 (48.9%)	96 (44.9%)
Baseline visual acuity in study eye (letters): Mean (SD)	60.7 (13.4)	59.4 (13.1)
Baseline GA in fellow eye: yes (%)	87 (8.7%)	63 (29.7%)
Baseline study eye CNV area (DA): mean (SD)	2.5 (2.5)	2.5 (2.6)
RAP lesion in study eye: yes (%)	112 (11.2%)	38 (17.8%)
Hemorrhage in study eye: yes (%)	606 (60.4%)	155 (72.4%)
Sub-RPE fluid in study eye: yes (%)	495 (53.0%)	106 (53.8%)

Ophthalmology Times Research Scholar Honoree Program



The association between baseline medication use with 5-year <u>incidence of GA</u> (N=1011)

	Medications No	Medication Yes	Multivariable Analysis*	
Systemic medications taken at baseline	Crude GA incidence in study eye (%)	Crude GA incidence in study eye (%)	Adjusted HR (95% CI)	p-value
Cholinesterase inhibitor	257/994 (25.9%)	8/17 (47.1%)	1.65 (0.80, 3.43)	0.18
ACE inhibitors	142/542 (26.2%)	123/469 (26.2%)	1.12 (0.87, 1.45)	0.38
Calcium channel blockers	189/736 (25.7%)	76/275 (27.6%)	1.17 (0.89, 1.54)	0.27
Beta-blocker	176/674 (26.1%)	89/337 (26.4%)	1.01 (0.78, 1.32)	0.93
Diuretics	158/593 (26.6%)	107/418 (25.6%)	1.00 (0.77, 1.29)	0.98
Aspirin	163/584 (27.9%)	102/427 (23.9%)	0.91 (0.70, 1.18)	0.48
Steroids	232/885 (26.2%)	33/126 (26.2%)	1.29 (0.87, 1.90)	0.21

Ophthalmology Times

Research Scholar

* Using no mediation as reference group, adjusted by age, smoking status, drug, treatment regimen, baseline visual acuity in study eye, baseline CNV area, RPA lesion, GA in fellow eye, subretinal tissue complex, intraretinal fluid, subretinal fluid, and AREDS severity scale.

The association between baseline medication use with 5-year incidence of GA (N=1011) Scheie Eve Institute

Renn Medicine

	Medications No	Medication Yes	Multivariable Analysis*	
Systemic medications taken at baseline	Crude GA incidence in study eye (%)	Crude GA incidence in study eye (%)	Adjusted HR (95% CI)	p-value
Statin	130/515 (25.2%)	135/496 (27.2%) 1.19 (0.92, 1.53		0.18
Iron medication (all doses)	259/996 (26.0%)	6/15 (40.0%)	1.52 (0.68, 3.42)	0.31
Iron medication (50mg or more)	261/1001 (26.1%)	4/10 (40.0%)	1.86 (0.69, 4.99)	0.22
Iron supplements	228/868 (26.3%)	37/143 (25.9%)	1.15 (0.80, 1.65)	0.46
Hormone replacement (females only)	253/977 (25.9%)	12/34 (35.3%)	1.35 (0.76, 2.41)	0.31
Drug targeting G protein coupled receptors	239/906 (26.4%)	26/105 (24.8%)	0.98 (0.64, 1.51)	0.94
Antacid	247/954 (25.9%)	18/57 (31.6%)	1.20 (0.74, 1.93)	0.47

Ophthalmology Times

Research Scholar

* Using no mediation as reference group, adjusted by age, smoking status, drug, treatment regimen, baseline visual acuity in study eye, baseline CNV area, RPA lesion, GA in fellow eye, subretinal tissue complex, intraretinal fluid, subretinal fluid, and AREDS severity scale.

The association between baseline medication with <u>GA growth</u> during 5-year CATT (N=214)



			Univariable Analyses		Multivariable Analyses*	
Systemic medications taken at baseline		Frequency (%)	Mean GA Growth Rate mm/year (SE)	p-value	Mean Growth Rate mm/year (SE) ¹	p-value
Calcium channel blockers	Yes	58 (27.1%)	0.38 (0.05)	0.06	0.40 (0.05)	0.02
	No	156 (72.9%)	0.31 (0.02)		0.30 (0.02)	
Steroids (Oral)	Yes	5 (2.3%)	0.57 (0.12)	0.04	NA	NA
	No	209 (97.7%)	0.32 (0.02)		NA	

Ophthalmology Times Research Scholar Honoree Program

*Adjusted by drug, treatment regimen, baseline GA in fellow eye, hemorrhage, and sub-RPE fluid.

Conclusions:



- In the eyes treated with anti-VEGF for exudative AMD, no significant association between <u>GA development</u> with cholinesterase inhibitor, ACE inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein-coupled receptors.
- <u>Calcium channel blockers</u> were associated with <u>higher growth rate of</u> <u>GA</u>, which requires validation in future studies.



Acknowledgement:



- Dr. Maureen Maguire
- Dr. Gui-Shuang Ying
- Center for Preventive Ophthalmology and Biostatistics at Penn
- CATT study group



References:

- Lancet Glob Health. 2014;2(2):e106-116.
- Ophthalmology. 2014;121(5):1079-1091.
- Ophthalmology. 2017;124(3):409-411.
- Retina Phila Pa. 2019;39(5):918-925.
- JAMA. 2012 Dec 19;308(23):2469-78.
- Am J Ophthalmol. 2007 Mar; 143(3): 473–483.



